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REVIEW
Abstract: Warfarin sodium is an effective oral anticoagulant drug. However, warfarin has a
narrow therapeutic window with significant risks of hemorrhage at therapeutic concentrations.
Dosing is difficult and requires frequent monitoring. New oral anticoagulant agents are required
to improve current anticoagulant therapy. Furthermore, while warfarin is effective in venous
disease, it does not provide more than 60% risk reduction compared with placebo in venous
thrombosis prophylaxis and considerably lower risk reduction in terms of arterial thrombosis.
Ximelagatran is an oral pro-drug of melagatran, a synthetic small peptidomimetic with direct
thrombin inhibitory actions and anticoagulant activity. As an oral agent, ximelagatran has a
number of desirable properties including a rapid onset of action, fixed dosing, stable absorption,
apparent low potential for medication interactions, and no requirement for monitoring of drug
levels or dose adjustment. It has a short plasma elimination half-life of about 4 hours in cases
of unexpected hemorrhage or need for reversal. Its main toxicity relates to the development of
abnormal liver biochemistry and/or liver dysfunction with “long-term” use of the drug. This
usually occurs within the first 6 months of commencing therapy, with a small percentage of
patients developing jaundice. The biochemical abnormality usually resolves despite
continuation of the drug. The cause of this toxicity remains unknown. Clinical studies to date
have shown that ximelagatran is noninferior to warfarin in stroke prevention in patients with
nonvalvular atrial fibrillation, noninferior to standard therapy as acute and extended therapy
of deep vein thrombosis (DVT), and superior to warfarin for the prevention of venous
thromboembolism post-major orthopedic surgery. It has also been shown to be more effective
than aspirin alone for prevention of recurrent major cardiovascular events in patients with
recent myocardial infarction.
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Introduction
Oral anticoagulants have been used in clinical practice for more than 60 years. The
most commonly prescribed oral anticoagulant has been warfarin sodium (either
Coumadin
® or Marevan®) or longer-acting coumarin preparations or indanedione
derivatives. Warfarin is an effective anticoagulant, but has a narrow therapeutic window
with significant risks of hemorrhage at therapeutic drug concentrations. This
unpredictable and variable pharmacological response necessitates frequent monitoring
of prothrombin time and reported as international normalized ratios (INR) and dose
adjustments. The potential for drug interactions, the influence of lifestyle factors on
INR (for example diet and alcohol consumption), and variable compliance by patients,
contribute significantly to limiting warfarin’s overall therapeutic benefit.
Thrombin has been recognized as having a principal role in the coagulation
pathways, hence the quest for its specific inhibition. Ximelagatran (Exanta
®
AstraZeneca, Molndal, Sweden) is an oral pro-drug of melagatran, a synthetic small
peptide direct inhibitor of thrombin with anticoagulant activity. Ximelagatran–
melagatran has a number of properties, which make it an attractive alternative to
warfarin sodium (see Table 1). It has predictable pharmacokinetics and
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pharmacodynamics with apparently no requirement for
routine anticoagulant monitoring with a fixed twice-daily
dose administration.
Ximelagatran has been investigated in several large
randomized controlled studies for prophylaxis against
venous thromboembolism occurring after major orthopedic
surgery, therapy in vein thrombosis, stroke prevention in
atrial fibrillation, and acute coronary syndromes.
Ximelagatran is now registered in France and other
European countries for the use in orthopedic prophylaxis.
In 2004, the application to market ximelagatran in the USA
was rejected by the Food and Drug Administration (FDA)
mostly due to concerns over potential liver toxicity. It is
timely to review the pharmacology and clinical experience
with this new oral anticoagulant drug.
Pharmacology
Melagatran is a small synthetic peptide with low membrane
permeability that is poorly absorbed after oral dosing. In
order to provide an oral formulation, ximelagatran, a pro-
drug of melagatran, was developed. The oral bioavailability
of ximelagatran is approximately 20% as measured by
melagatran concentration with low inter-individual
variability (coefficient of variation is 20%) (Eriksson et al
2003b, 2003d; Eriksson, Johansson, et al 2003; Johansson,
Andersson, et al 2003). Absorption of ximelagatran is rapid
and minimally influenced by food and other medications.
The peak plasma melagatran concentration is observed
1.5–2 hours after oral ximelagatran, a peak anticoagulant
effect equivalent to subcutaneous heparins. Bioavailability
does not appreciably change with repeated administration
(Eriksson et al 2003c, 2003e). After oral dosing, unabsorbed
ximelagatran passes unchanged through the intestine.
Ximelagatran undergoes rapid enzymatic conversion to
melagatran via 2 intermediates, ethyl-melagatran (from the
ethyl ester of melagatran formed by reduction of the
hydroxyl group) and hydroxyl-melagatran (the hydroxy-
amidine of melagatran, formed by hydrolysis of the ethyl
group) (see Figure 1) (Eriksson et al 2003d). This conversion
in vivo probably occurs in several tissues. Enzymatic
conversion in vitro occurs in microsomal preparations from
the liver, intestinal membrane, and kidney. The highest
activity was found in liver mitochondria. Cytochrome P450
(CYP) enzymes are unlikely to be involved in the
Table 1 Comparison of ximelagatran–melagatran and warfarin sodium
Property Warfarin sodium Ximelagatran–melagatran
Origin, source Synthetic Synthetic
Mechanism action Reduced synthesis functional prothrombin and Direct competitive and reversible thrombin
other clotting factors inhibition
Rapid onset action No Yes
Effective anticoagulant Yes Yes (not inferior to well-controlled warfarin
therapy in most studies)
Risk of hemorrhage Significant Equivalent to warfarin in most studies
Route administration Oral, once daily Oral, twice daily
Stable predictable pharmacokinetics No Yes
Interactions with diet and alcohol Clinically significant No
Interactions with other medications Many Possibly erythromycin
Dosing Individualized to patient and target INR Fixed dosing dependent on indication 
Monitoring dose INR every 1–2 weeks No
Dose adjustments Frequent No
Use in severe liver disease Problematic No – excluded from clinical studies
Use in severe renal disease Yes No – drug renally excreted, excluded from
clinical studies
Reversibility after cessation Slow elimination and reversal antithrombotic effect Rapid reversal dependent on elimination half-life
(~ 4 hours)
Antidote Rapid reversal with factor replacement. Possibly APCC and rFVIIa 
Reversal with vitamin K
Drug cost Cheap Marketed in Europe at €4 for 24 mg twice daily
regimen
Abbreviations: APCC, activated prothrombin complex concentrate; INR, international normalized ratios; rFVIIa, recombinant activated factor VII.Vascular Health and Risk Management 2006:2(1) 51
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bioconversion of ximelagatran as no reduction of hydroxyl-
melagatran was found in preparations of 9 different CYP
isoenzymes. The conversion of the intermediates to
melagatran occurs rapidly in all ethnic groups including
African, Asian, and Caucasian (Johansson, Andersson, et
al 2003). Hydroxyl-melagatran, as with ximelagatran, is an
ineffective thrombin inhibitor (potency ~1% of melagatran)
while ethyl-melagatran’s anticoagulant activity is the same
as melagatran (Gustaffson et al 2001).
Pharmocokinetics
Melagatran exhibits first-order absorption kinetics with no
significant protein binding (volume of distribution of
0.22 litres/kg). It is not significantly metabolized, with 80%
renally excreted over 24 hours (Eriksson et al 2003a).
Melagatran has a relatively short plasma elimination half-
life of 1.5–2 hours in young healthy subjects. With
increasing age, the plasma elimination half-life of
melagatran increases to 4–5 hours as a consequence of age-
related decrease in renal function.
In a small randomized crossover study (Eriksson et al
2003b) of 12 volunteers with severe renal impairment, the
half-life and area under the plasma concentration–time curve
of melagatran given in clinically relevant amounts was
significantly higher. The optimal dose and schedule in
patients with renal impairment is yet to be determined.
No significant difference was noted in the pharmaco-
kinetics or pharmacodynamics in patients with mild to moderate
hepatic impairment (Johansson, Wahlander, et al 2003).
Ximelagatran seemed to have a low potential for
interaction with concomitant medications in clinical studies
involving over 17 000 patients. Studies of possible
interactions of ximelagatran–melagatran with alcohol, or
other medications (including nifedipine, diazepam,
diclofenac, acetylsalicylic acid, digoxin, and statins) have
been negative. Therefore the metabolism of ximelagatran–
melagatran is independent of CYP enzymes. Coadministra-
tion of ximelagatran and erythromycin has been shown to
increase the area under the curve of melagatran by 80%
(Dorani et al 2004). This interaction between ximelagatran
and erythromycin may involve a transport protein such as
P-glycoprotein. Dose adjustment for obesity (Body mass
index [BMI] up to 39 kg/m
2) has not been found to be
necessary as evidenced by an open label, single dose of
24 mg ximelagatran in obese subjects (BMI 32–39 kg/m
2)
compared with sex and age-matched, nonobese subjects
(BMI 21–26 kg/m
2) (Sarich, Teng, et al 2003).
Antithrombotic activity of
melagatran
Melagatran is a potent, competitive, and reversible direct
inhibitor binding to the active site of soluble and clot-bound
α-thrombin. Ximelagatran has no pharmacodynamic effect.
Melagatran’s antithrombotic properties may be broadly
categorized including inhibition of thrombin, inhibition of
platelet aggregation, and other effects including augmented
fibrinolysis (see Figure 2).
Effects on thrombin
Melagatran inhibits coagulation by antagonism of the
thrombin-mediated cleavage of fibrinogen to fibrin as well
as the cascade of interrelated events responsible for its
anticoagulant activity, such as activation of clotting factors.
Figure 1 Chemical structure of ximelagatran and melagatran.Vascular Health and Risk Management 2006:2(1) 52
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This is evident by its prolongation of activated partial
thromboplastin time (APTT), prothrombin time (PT), and
thrombin clotting times at clinically relevant concentrations
(doubling of clotting times at 0.59, 2.2, and 0.01 µmol/L,
respectively). Capillary bleeding time was also prolonged
by 36 seconds in 12 male volunteers after a single
subcutaneous dose of melagatran and returned to baseline
within 8 hours (Johansson, Wahlander, et al 2003).
 The effect
on skin bleeding time has not been documented.
Effects on platelet aggregation
Several studies demonstrated that melagatran can inhibit
thrombin-induced platelet activation and/or aggregation in
a concentration-dependent manner (Gustaffson et al 1998;
Soslau et al 2002; Nylander and Mattson 2003). Effects of
melagatran on platelet activation appear to involve thrombin
bound to glycoprotein Ib and also activation of protease
activated receptor-4 (PAR-4) (Soslau et al 2002) and PAR-1
(Nylander and Mattson 2003).
Other effects of thrombin inhibition
Melagatran appears to enhance endogenous fibrinolysis with
no inhibitory effect on tissue plasminogen activator (t-PA)-
induced fibrinolysis (Mattson et al 2000). This effect appears
to be due to melagatran’s inhibition of thrombin-mediated
activation of TAFI (thrombin activable fibrinolysis inhibitor;
pro-carboxypeptidase U) to activated TAFI. Two clinical
studies have confirmed the absence of inhibition of
fibrinolysis by therapeutic melagatran concentrations
(Eriksson et al 1999; Eriksson, Wahlander, et al 2003).The
melagatran effect on other thrombin-mediated effects
including thrombomodulin and activation of endothelial
cells is not clear.
Reversal of the antihemostatic effect
Whilst there are antidotes for heparin (protamine) and
warfarin (vitamin K or prothrombin complex concentrate),
no antidote is available for the rapid reversal of ximela-
gatran–melagatran. Prothrombin factor replacement, as
plasma or concentrate, would not be expected to reverse
the direct thrombin inhibition, which is dependent on plasma
concentration. Removal of melagatran from plasma by
dialysis is possible with some dialysis membranes.
Overcoming the thrombin inhibition by administration of
activated clotting factors seems the most promising method.
Activated prothrombin complex concentrate (APCC) has
been found to reduce in a dose dependent manner the
bleeding time and blood loss produced by high concen-
trations of melagatran in rats and rabbits. Activated factor
VII (FVIIa) appeared less effective than APCC in these
models. However, human FVIIa binds poorly to rat tissue
factor (TF) and activates rat factor X poorly in the absence
of TF, and this may account for some the differences noted
(Elg et al 2002). Clinical studies to define an effective
strategy for managing unexpected hemorrhage are required.
Clinical studies
With the potential advantages of clinical efficacy and safety,
ximelagatran–melagatran has been assessed in an expansive
clinical study program (Table 2). The studies can be broadly
categorized into: stroke prevention in atrial fibrillation;
prophylaxis for venous thromboembolism after major
orthopedic surgery; treatment of vein thrombosis; and in
acute coronary syndromes. As with most clinical studies,
patients with severe renal disease, hepatic disease, and
pregnant patients were excluded from the ximelagatran
clinical study program. Further studies will need to address
the efficacy and safety of ximelagatran in these patient
groups.
Stroke prevention in atrial fibrillation
Nonvalvular atrial fibrillation (NVAF) affects 6% of people
over the age of 65 years and about 10% of those over 80
years. These patients have an absolute risk of stroke and
systemic embolism of around 5%, not including the effects
of other risk factors. There is conclusive evidence to
demonstrate that warfarin sodium, given to achieve a target
INR of 2–3, is highly effective at preventing stroke with a
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Figure 2 Antithrombotic activity of ximelagatran is mediated by direct
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risk reduction of 62%. However, this is associated with a cost
of around 1% per year of fatal hemorrhage. Despite the
published efficacy of warfarin, only 20%–40% of
eligible patients actually receive warfarin (Bungard et al 2000).
Ximelagatran has been evaluated in at least 2 dose-
finding exploratory studies (SPORTIF II and IV) and 2 large
Phase III studies (SPORTIF [Stroke Prevention using an
ORal Thrombin Inhibitor in atrial Fibrillation] III and V)
recruiting about 8000 patients with atrial fibrillation.
An open label study (SPORTIF III) (Olsson 2003) of
3407 European patients with NVAF at moderate risk of
stroke or systemic embolism was conducted while the
SPORTIF V study (Halperin et al 2003) examined 3922
North American patients using a double-blind comparison
Table 2 Summary of clinical development of ximelagatran–melagatran
Type of Number of
Study and patient group study subjects Treatment allocation
Nonvalvular atrial fibrillation
(Stroke Prevention using an ORal Thrombin Inhibitor in atrial Fibrillation–SPORTIF)
SPORTIF II (Petersen et al 2003) Dose finding 254 Ximelagatran (20, 40, or 60 mg twice daily) or warfarin to INR 2–3.
SPORTIF III (Olsson et al 2003)  RCT open label 3407 Ximelagatran (36 mg twice daily) or warfarin to INR 2–3
SPORTIF IV Dose finding 167 Ximelagatran (36 mg twice daily) or warfarin to INR 2–3 for 2–5 years
SPORTIF V (Halperin et al 2003) RCT double-blind 3922 Ximelagatran (36 mg twice daily) or warfarin to INR 2–3 for 20 months
Prophylaxis for venous thromboembolism after major orthopedic surgery
(MElagatran as prophylaxis of THrombosis in ORthopedic surgery – METHRO)
METHRO I – Hip or knee surgery Randomized dose finding 135 Melagatran–ximelagatran (pre- and postoperative melagatran 1, 2, or 4 mg
(Eriksson, Arfwidsson, et al 2002 for 3 doses followed by ximelagatran 6, 12, or 24 mg twice daily for 8–11
days) or dalteparin 5000 IU once daily started preoperatively
METHRO II – Hip or knee surgery
  Phase II randomized 1916 Melagatran–ximelagatran (preoperative melagatran 1, 1.5, 2.25 or 3 mg
(Eriksson, Bergqvist, et al 2002) double-blind dose finding followed by postoperative melagatran or ximelagatran 8, 12, 18 or 24 mg
twice daily for 8–11 days) or dalteparin 5000 IU once daily started pre-
operatively
METHRO III – Hip or knee Phase III randomized 2788 Melagatran–ximelagatran (postoperative melagatran 3 mg followed by
surgery (Eriiksson et al 2003a) double-blind ximelagatran 24 mg twice daily) or enoxaparin 40 mg once daily started
pre-operatively
EXPRESS – Hip or knee surgery Phase III randomized 2885 Melagatran–ximelagatran (melagatran preoperatively 2 mg, melagatran 12
(Eriksson et al 2003b) double-blind hours postoperatively 3 mg, then ximelagatran 24 mg twice daily) or
enoxaparin 40 mg once daily
EXULT A – Knee surgery Phase III randomized 2301 Ximelagatran (24 mg or 36 mg bd twice daily, initiated the morning after
(Francis, Berkowitz, et al 2003) double-blind surgery) or warfarin initiated evening of the day of surgery for 7–12 days
EXULT B – Knee surgery Phase III randomized 2303 Ximelagatran (36 mg bd twice daily initiated the morning after surgery) or
(Colwell et al 2003) double-blind warfarin initiated evening of day of surgery for 7–12 days
Therapy: DVT without symptomatic PE
(THRombin Inhibitor in Venous thromboEmbolism – THRIVE) 
THRIVE I – Acute DVT Randomized dose finding 350 Ximelagatran (24, 36, 48, 60 mg twice daily) or dalteparin + warfarin
(Eriksson, Wahlander, et al 2003)
THRIVE II and V – Acute DVT Phase III double-blind  2491 Ximelagatran 36 mg twice daily for 6 months or enoxaparin
with or without PE
 (Francis, RCT 1 mg/kg/bid + warfarin to INR 2–3 for 6 months
Ginsberg, et al 2003)
THRIVE III – Extended anticoa Phase III 1223 Ximelagatran 24 mg twice daily or placebo
gulation for DVT or PE
(Schulman et al 2003)
THRIVE IV – Acute PE  Limited dose finding 12 Ximelagatran (48 mg twice daily) for 2 weeks with lung scanning days 1
(Wahlander et al 2001) in PE and 7 and pharmacokinetic data
Long term treatment in high risk arterial thrombotic events – post-MI patients
ESTEEM study – acute MI Randomized dose 1883 Ximelagatran (24, 36, 48, 60 mg twice daily) or placebo.  All patients
(Wallentin et al 2003) finding received aspirin 160 mg once daily.
Abbreviations: DVT; deep vein thrombosis; INR, international normalized ratios; PE, pulmonary embolism; MI, myocardial infarction; RCT, randomized controlled trial.Vascular Health and Risk Management 2006:2(1) 54
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(Halperin et al 2003). The aims of these 2 studies were to
demonstrate noninferiority of a fixed dose of ximelagatran
of 36 mg twice daily compared with warfarin. The rates of
stroke and systemic embolism for warfarin and ximelagatran
were 2.3% per year and 1.6% per year in SPORTIF III with
no significant difference between groups in rates of major
bleeding, although there was less total bleeding with
ximelagatran (37% vs 47% per year, 95% Confidence Index
[CI] for the difference, –14% to –6.0% per year; p < 0.001).
These studies, both separately and in pooled analysis, did
not find any significant difference between warfarin and
ximelagatran in treated groups and hence demonstrated the
noninferiority of 36 mg of ximelagatran.
There was no significant difference in the rates of fatal/
major bleeding between warfarin and ximelagatran groups
(SPORTIF III 1.8% and 1.3%; SPORTIF V 3.1% and 2.4%
for warfarin and ximelagatran, respectively), although there
was a slight excess of total bleeding in warfarin-treated
patients (SPORTIF III 29.5% and 25.5%, p = 0.007;
SPORTIF V 47% and 37%, p < 0.0001). Alanaine transa-
minase (ALT) was above 3 times upper limit of normal
(ULN) in 0.8% and 1% of warfarin-treated compared with
6% of ximelagatran-treated patients in both SPORTIF III
and V. The conclusion of these studies is that ximelagatran
36 mg twice daily was not inferior to warfarin with target
of 2–3.
A number of concerns have been raised concerning the
use of ximelagatran for stroke prophylaxis in chronic atrial
fibrillation. This relates to trial designs (noninferiority), cost
of the drug, and need for liver function monitoring. The
noninferiority design makes it possible that ximelagatran
was in fact a slightly inferior treatment than warfarin
(Eikelboom and Hankey 2004). A detailed cost analysis of
ximelagatran has been published (O’Brien and Gage 2005).
The overall conclusions of this analysis were that, assuming
equal effectiveness in stroke prevention and decreased
hemorrhage risk, ximelagatran is not likely to be cost-
effective in patients with atrial fibrillation unless they have
a high risk of intracranial hemorrhage or low quality of life
with warfarin.
Prophylaxis for venous
thromboembolism occurring after
major orthopedic surgery
Without prophylaxis, arthroplasty surgery of the knee and
hip (range 40%–84%) carry high risks of post-operative vein
thrombosis and death from pulmonary embolism (PE)
(Geerts et al 2004). Standard prophylaxis generally includes
early mobilization, compression stockings, and daily low-
molecular-weight heparin (LMWH) for 5–10 days. With
these general measures, 1%–2% of patients will develop
symptomatic DVT or PE. Fatality rates over the 6-week
postoperative period range from 0.1% to 0.5%, most clinical
events occurring out of hospital. Recent studies using
LMWH as prolonged prophylaxis for 4–6 weeks after hip
surgery have shown significantly reduced symptomatic
venous thromboembolism (Eikelboom et al 2001). In North
America, about 50% of patients receive warfarin prophylaxis
post knee replacement surgery.
Given the high rates of venous thromboembolism, major
orthopaedic surgery provides an opportunity for more
effective anticoagulants to improve clinical outcomes.
Studies of standard prophylaxis with bilateral leg contrast
venography performed 7–14 days after hip or knee
replacement surgery find total DVT rates of 15%–30%
respectively and proximal DVT rates of about 6% in both
groups.
There have been extensive studies of the use of
ximelagatran–melagatran after joint replacement surgery
(see Table 2). METHRO I (Melagatran as prophylaxis of
thrombosis in orthopaedic surgery), a dose-ranging pilot
study, and METHRO II (Eriksson, Arfwidsson, et al 2002;
Eriksson, Bergqvist, et al 2002), a phase II study, have found
an overall dose-dependent decrease in venographic total and
proximal DVT and/or symptomatic PE with increasing doses
of ximelagatran–melagatran. The METHRO III study
compared the use of ximelagatran–melagatran with
enoxaparin in a randomized study of 2788 patients
undergoing major orthopedic surgery. Doses of enoxaparin
were 40 mg once daily commencing 12 hours preoperatively
then daily for 1–10 days compared with melagatran 3 mg
subcutaneously 4–12 hours postoperatively, then
ximelagatran 24 mg orally twice daily commencing on day
1 or 2 postoperatively
 (Eriksson et al 2003a). Using bleeding
or efficacy as endpoints, no difference was demonstrated in
this study.
The EXPRESS study (EXpanded PRophylaxis
Evaluation Surgery Study), similar in design to METHRO
III with the exception that ximelagatran–melagatran-treated
patients received 2 mg of melagatran preoperatively (Eriksson
et al 2003b), demonstrated a total venographic DVT rate of
20.3% in the ximelagatran–melagatran group compared with
26.6% in enoxaparin-treated patients (p < 0.0001). There was
no difference in the rates of venographic proximal DVT,
symptomatic events or bleeding.Vascular Health and Risk Management 2006:2(1) 55
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The EXULT (EXanta Used to Lessen Thrombosis) trials
(Colwell et al 2003; Francis, Berkowitz, et al 2003),
investigated 4604 patients in North America, randomized
to receive either postoperative oral ximelagatran (24 mg or
36 mg twice daily) or warfarin (target INR 2.5). EXULT A
study found that ximelagatran 36 mg twice daily was more
effective than warfarin (total venographic vein thrombosis
rate of 20.3% versus 27.6 % (p = 0.003). These results were
confirmed in the EXULT B study (Collwell et al 2003).
Bleeding events did not differ.
The overall conclusions of these studies are that
ximelagatran with perioperative melagatran is a suitable
prophylaxis regimen for patients undertaking arthroplasty
surgery. Omission of the preoperative melagatran dose,
while resulting in decreased surgical site bleeding, may
compromise efficacy, particularly using ximelagatran 24 mg.
Ximelagatran–melagatran was approved in October 2004
in several European countries for venous thrombo-
emobolism (VTE) prophylaxis in hospitalized patients
undergoing joint replacement surgery.
Therapy of vein thrombosis
Current acute therapy of venous thromboembolism, either
DVT or PE, requires initial anticoagulation with parenteral
heparin and subsequently vitamin K antagonists in most
patients. Many patients can be treated safely out of hospital
using LMWH, with warfarin usually initiated 24–48 hours
after commencement, but usually requiring at least 1 week
to establish therapeutic anticoagulation. Heparin and
warfarin are overlapped for minimum of 5 days and for 2
days of consecutive INR readings in the target range of 2–3
(Geerts et al 2004). Optimal duration of warfarin therapy
remains uncertain. Most patients with first provoked DVT
or PE require 3–6 months of treatment; this is generally
extended to 6–12 months if the vein thrombosis was
unprovoked. Patients with unprovoked DVT and/or PE have
a higher rate of recurrence of about 1 in 3 over 10 years.
(Kearon et al 1999) Extension of warfarin therapy, with a
target INR of 2.0–3.0, has been shown in a number of studies
to be 90%–95% effective for prevention of recurrent
thrombosis. Due to the unpredictable risk of major/fatal
hemorrhage, most patients with first unprovoked DVT/PE
cease warfarin after 6–12 months. Extension of therapy
should be reserved for patients with recurrent DVT or
significant thrombophilia.
The THRIVE (THRombin Inhibitor in Venous thrombo-
Embolism) studies have evaluated ximelagatran compared
with standard anticoagulation for acute treatment of DVT
(THRIVE I, THRIVE II, and THRIVE V) (Eriksson,
Wahlander, et al 2003; Francis, Ginsberg, et al 2003) or
compared with placebo for extended secondary prevention
(THRIVE III)
 (Schulman et al 2003).
THRIVE II and V (Francis, Ginsberg, et al 2003) were
randomized double-blind studies in which 2489 patients
with acute DVT (37% with asymptomatic PE), mean age of
57 years with 53% male, were allocated to ximelagatran
36 mg twice daily for 6 months or standard therapy with
enoxaparin and warfarin targeted to INR 2–3 for 6 months.
No coagulation monitoring was performed for ximelagatran-
treated patients although sham INRs were performed.
Intention to treat analysis found 2.1% and 2.0% of
ximelagatran- and warfarin-treated patients developed
recurrent symptomatic venous thrombembolism respectively
(absolute difference 0.1%, 95% CI 1.0–1.3%). The
conclusion of the THRIVE study was that ximelagatran was
noninferior compared with standard therapy. There was no
difference in major hemorrhage (1.3% vs 2.2%) or all-cause
mortality (2.3% vs 3.4%) between ximelagatran- or
warfarin-treated patients. Enrolled patients may have been
at low risk for VTE as evidenced by the lower rate of
recurrent VTE regardless of treatment assignment (1.5%–
2.1%) compared with the typical expected rate of 3%–6%
in patients receiving standard treatment with either
unfractionated heparin (UFH) or LMWH.
The THRIVE III study (Schulman et al 2003)
randomized 1233 patients in a double-blind fashion to
receive placebo or ximelagatran 24 mg twice daily for 18
months after completion of 6 months’ anticoagulant therapy
for acute DVT or PE. The cumulative risk of symptomatic
recurrent vein thrombosis was 2.8% in ximelagatran and
12.6% in the placebo-treated subjects (Risk Ratio [RR] 0.16,
95% CI 0.09–0.3, p < 0.001). Deaths occurred in 6 and 7
ximelagatran- and placebo-treated patients, respectively
(0 and 3 from PE). Major, nonfatal hemorrhage occurred in
6 of 612 and 5 of 611 ximelagatran- and placebo-treated
patients, respectively.
The overall conclusions of these studies are that
ximelagatran is not inferior to standard therapy for the acute
therapy of DVT and is superior to placebo for extended
secondary prevention of recurrent DVT and/or PE.
Treatment of acute coronary
syndromes
Anticoagulation therapy in acute coronary artery disease
depends on multiple factors, with selection of agentsVascular Health and Risk Management 2006:2(1) 56
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depending on the presence of acute coronary syndromes,
need for bypass surgery, or planned percutaneous coronary
intervention, or prophylaxis after a negative cardiovascular
event. Anticoagulant therapies have long been thought to
provide marginal or modest benefit in patients with acute
coronary disease. Most recent studies have rekindled interest
with warfarin or warfarin with low-dose aspirin providing
about 20% relative risk reductions in recurrent ischemia,
reinfarction, and death.
The ESTEEM (Efficacy and safety of the oral direct
thrombin inhibitor ximelagatran in patients with recent
myocardial damage) study (Wallentin et al 2003) was a phase
II study assessing the efficacy and safety of ximelagatran in
preventing recurrent acute coronary syndromes in 1833
patients within 14 days of myocardial infarction (MI).
Patients were randomly assigned to receive aspirin 160 mg
once daily or aspirin 160 mg once daily with ximelagatran
(24, 36, 48, or 60 mg twice daily). The primary endpoint
was a composite of recurrent nonfatal MI, recurrent
ischemia, or death (from any cause). On an intention-to-
treat analysis the primary endpoint occurred in 12.7% and
16.3% of ximelagatran plus aspirin- or aspirin alone-treated
patients (RR 0.79, 95% CI 0.59–0.98, p = 0.036). Major
bleeding occurred in 1.8% and 0.9% of patients (not
statistically different). This trial suggests that the addition
of ximelagatran to aspirin may reduce the rate of death and/
or cardiovascular thrombotic outcomes. Larger phase III
studies are needed to confirm this.
Tolerability and patient acceptability
Aside from hemorrhage, ximelagatran–melagatran has been
remarkably free of significant adverse toxicities. Most
concern has been placed on the dose-dependent increase in
liver enzymes, predominantly elevated ALT, which is usually
unaccompanied by clinical sequelae. This has been found
in 6%–12% of patients in clinical studies with the
biochemical abnormality typically occurring in 1–6 months
of therapy, rarely developing after 6 months of treatment.
In all clinical studies, patients required monthly screening
of liver biochemistry in the first 6 months. The study
medication was ceased if ALT exceeded 5 times ULN at
any time. If ALT was 3–5 times ULN, more frequent
monitoring was performed with 6% of patients overall of
increased ALT to > 3 times ULN. Only about one-half of
patients discontinued the study as a result of this. With time,
the ALT tends to decrease whether or not the drug is
discontinued although a small percentage (data unpublished)
still has persistent elevation. However, a small percentage
of patients became jaundiced (0.4% in the ESTEEM study)
or developed symptoms possibly attributable to liver
dysfunction. The FDA analysis of longer-term exposure to
ximelagatran suggests that signs of liver injury as reflected
by elevations of ALT levels were typically observed after
1–2 months in approximately 6% of patients. The
mechanism underlying the liver abnormality remains
unclear, with further information from clinical studies
required, particularly in view of the recent FDA concern
which has resulted in nonapproval of ximelagatran. If
ximelagatran is to be prescribed for more prolonged periods
(other than short term prophylaxis), liver function should
be monitored. This may offset the improved acceptability
of the drug in terms of need for monitoring. In the short
term, the lack of monitoring required should improve
compliance, although twice daily dosing may be seen as
more inconvenient than the once daily dosing required for
warfarin. However, only fixed doses are required, compared
with variable doses of warfarin.
The FDA also inferred a higher than expected increase
in rate of MI from the orthopedic prophylaxis studies. This
post-hoc analysis involved small numbers of events, the
comparison between ximelagatran and standard therapy was
not statistically significant, and MI was not an adjudicated
endpoint. In the METHRO III study, 2 patients suffered MI
during the treatment period and 1 succumbed to cardiogenic
shock in the follow up period. No such event occurred in
the control arm. Cardiomyopathy, ischemic heart disease,
and congestive heart failure were causes of 3 deaths in the
ximelagatran group in the METHRO II studies. No
comments were made by the authors as to potential reasons
for these adverse events or their significance. Similar
findings regarding MI were not observed in the other clinical
studies of ximelagatran.
Conclusion
The clinical studies of ximelagatran confirm that it is an
effective antithrombotic agent in stroke prevention in
nonvalvular atrial fibrillation, prevention, and therapy of
venous thromboembolism, and possibly in preventing
recurrent ischemia after acute MI. In most clinical
indications, the conclusion from the studies is that
ximelagatran is noninferior to well controlled warfarin
therapy with respect to efficacy without increased bleeding
propensity. In comparison with warfarin, ximelagatran has
several desirable properties in terms of administration,
dosing, and monitoring. Moreover, the minimal impact of
diet and seeming lack of significant medication interactionsVascular Health and Risk Management 2006:2(1) 57
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make it a significantly more desirable therapeutic option
over warfarin.
The major drawback of ximelagatran relates to its
potential liver toxicity and need for monitoring of liver
biochemistry for at least the first 6 months of treatment.
Five percent to 10% of patients will develop ALT greater
than 3 times ULN, leading to discontinuation of their
medication. Unfortunately, the proposed Risk Minimization
Action Plan (RiskMAP) submitted by AstraZeneca as part
of its new drug application was felt to be inadequate by the
FDA (http://www.fdaadvisorycommittee.com/). Further-
more, other similar monitoring programs using transaminase
elevations as a marker of hepatotoxicity with medications
such as bromfenac and troglitazone, failed to demonstrate
effectiveness in prevention of severe drug-induced liver
injury. Understanding the pathophysiology behind this
predominantly biochemical adverse effect of ximelagatran–
melagatran would thus be beneficial and necessary for the
development of a useful and acceptable risk minimization
program.
Ximelagatran is a new oral antithrombotic drug, which
will effectively benefit many patients and have a major role
in clinical practice. Precaution concerning the risk of
hepatotoxicity should be further investigated and not
discourage the important and growing need for alternative
oral anticoagulant therapies.
Disclosure
Dr Tim Brighton receives honoraria as an occasional
speaker, clinical investigator, and consultant for
AstraZeneca, Pfizer (formerly Pharmacia), and Sanofi-
Aventis.
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